Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Amylyx Pharmaceuticals, Inc.

< Previous 1 2 3 Next >
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Launch of Public Offering
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Stock Trading Halted Today
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for Second FDA Advisory Committee Meeting on AMX0035
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces FDA Advisory Committee Will Reconvene to Review New Drug Application for AMX0035 for the Treatment of ALS on September 7, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Partnership Agreement with Sunnybrook Research Institute to Identify Novel Drug Candidates for Neurodegenerative Diseases
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals to Announce Plans for an Open Label Extension (OLE) Phase for Global PHOENIX Trial of AMX0035 in ALS at the 17th International Congress on Neuromuscular Diseases
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces FDA Plan to Reconvene Advisory Committee to Review AMX0035 NDA for the Treatment of ALS on September 7, 2022
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Tickers AMLX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.